维格列汀联合阿卡波糖治疗2型糖尿病的疗效及安全性

Efficacy and Safety of Vitagliptin Combined with Acarbose in the Treatment of Type 2 Diabetes

目的 研究2型糖尿病(T2DM)患者采用维格列汀联合阿卡波糖治疗的价值。方法 研究时段是2017年1月至2019年6月,研究对象是我院收治的60例T2DM患者,按“入院先后顺序”随机分观察组(维格列汀联合阿卡波糖)与对照组(阿卡波糖)各30例,两组比较胰岛β细胞功能、治疗效果及不良反应。结果 治疗前,观察组患者FCP指标为(0.95±0.42)ng/mL,2 hFCP指标为(1.96±0.42)ng/mL,FINS指标为(12.47±1.83)μU/mL,2 hFINS指标为(46.89±3.84)μU/mL。治疗前,对照组患者FCP指标为(0.89±0.15)ng/mL,2 hFCP指标为(1.73±0.85)ng/mL,FINS指标为(13.06±0.58)μU/mL,2 hFINS指标为(47.82±2.39)μU/mL。治疗后,观察组患者FCP指标为(1.74±0.72)ng/mL,2 hFCP指标为(4.59±0.92)ng/mL,FINS指标为(15.69±0.71)μU/mL,2 hFINS指标为(66.54±6.48)μU/mL。治疗后,对照组患者FCP指标为(1.03±0.22)ng/mL,2 hFCP指标为(2.61±1.18)ng/mL,FINS指标为(12.73±0.64)μU/mL,2 hFINS指标为(50.13±5.26)μU/mL。观察组患者治疗显效患者16例占比53.33%,治疗好转患者13例占比43.33%,治疗无效患者1例占比3.33%,治疗总有效率96.67%。对照组患者治疗显效患者14例占比46.67%,治疗好转患者9例占比30.00%,治疗无效患者7例占比23.33%,治疗总有效率76.67%。60例患者治疗后,观察组胃肠道不适1例,恶心呕吐1例,未发生低血糖,不良反应发生率6.67%;对照组胃肠道不适3例,恶心呕吐4例,低血糖1例,不良反应发生率26.67%。观察组不良反应发生率较对照组低(χ^(2)=4.3200,P=0.0376),P <0.05。结论 维格列汀联合阿卡波糖治疗T2DM患者能提高整体疗效、改善胰岛β细胞功能,说明联合用药能发挥各自优势,弥补单纯用药的不足,避免机体发生恶心呕吐、低血糖等不良反应,提高用药安全性、整体疗效,控制血糖波动、加速疾病康复进程,获得良好的治愈疾病效果,得到患者青睐、满意,临床应用较广泛,值得推崇。

Objective To study the value of vildagliptin combined with acarbose in patients with type 2 diabetes mellitus(T2DM).Methods The study period was from January 2017 to June 2019,and the research objects were 60 patients with T2DM admitted to our hospital.According to the“admission order”,they were randomly divided into an observation group(vildagliptin combined with acarbose)and a control group(acarbose).30 cases in each group,the isletβ-cell function,therapeutic effect and adverse reactions were compared between the two groups.Results Before treatment,the FCP index of the observation group was(0.95±0.42)ng/mL,the 2 hFCP index was(1.96±0.42)ng/mL,the FINS index was(12.47±1.83)μU/mL,and the 2 hFINS index was(46.89±3.84)μU/mL.Before treatment,the FCP index of the control group was(0.89±0.15)ng/mL,the 2 hFCP index was(1.73±0.85)ng/mL,the FINS index was(13.06±0.58)μU/mL,and the 2 hFINS index was(47.82±2.39)μU/mL.After treatment,the FCP index of the observation group was(1.74±0.72)ng/mL,the 2 hFCP index was(4.59±0.92)ng/mL,the FINS index was(15.69±0.71)μU/mL,and the 2 hFINS index was(66.54±6.48)μU/mL.After treatment,the FCP index of the control group was(1.03±0.22)ng/mL,the 2 hFCP index was(2.61±1.18)ng/mL,the FINS index was(12.73±0.64)μU/mL,and the 2 hFINS index was(50.13±5.26)μU/mL.In the observation group,16 patients with marked effect accounted for 53.33%,13 patients with improved treatment accounted for 43.33%,1 patient with ineffective treatment accounted for 3.33%,and the total effective rate was 96.67%.In the control group,14 patients with marked effect accounted for 46.67%,9 patients with improved treatment accounted for 30.00%,7 patients with ineffective treatment accounted for 23.33%,and the total effective rate was 76.67%.After treatment of 60 patients,1 case of gastrointestinal discomfort,1 case of nausea and vomiting in the observation group,and no hypoglycemia occurred,incidence of adverse reactions 6.67%;3 cases of gastrointestinal discomfort,4 cases of nausea and vomiting,and 1 case of hypoglycemia,incidence of adverse reactions 26.67%in the control group.Occurred the incidence of adverse reactions in the observation group was lower than that in the control group(χ^(2)=4.3200,P=0.0376),P<0.05.Conclusion Vildagliptin combined with acarbose in the treatment of T2DM patients can improve the overall efficacy and improve isletβ-cell function,indicating that the combined drug can exert its respective advantages,make up for the lack of simple drug use,and avoid the occurrence of nausea,vomiting,hypoglycemia and other toxic side effects.It can improve the safety and overall efficacy of medication,control blood sugar fluctuations,accelerate the process of disease recovery,and obtain a good effect of curing diseases,which is favored and satisfied by patients.It has a wide range of clinicalapplications and is worthy of praise.